
Opinion|Videos|June 23, 2025
Overcoming Challenges for Wider Adoption of TLX250
Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial nephrectomy, though anatomical details would still require conventional imaging.
Advertisement
Episodes in this series

Complex Renal Masses and Molecular Imaging
Main Discussion Topics:
- Challenges of managing anatomically complex renal masses
- Potential for molecular imaging to influence nephron-sparing decisions
- Tumors with aggressive biology may warrant radical nephrectomy, whereas those with indolent biology may be candidates for partial nephrectomy.
- Limitations in anatomic resolution compared with MRI
Key Points for Physicians:
- Molecular characteristics may influence decisions regarding partial vs radical nephrectomy.
- Aggressive biology might favor radical approach, even when partial is technically feasible.
- Indolent biology might support nephron sparing, even in challenging cases.
- Molecular imaging should complement rather than replace high-resolution anatomic imaging.
Notable Insights:
Molecular imaging provides biological rather than anatomic information and should be used in conjunction with conventional imaging for optimal decision-making.
Clinical Significance:
Integrating molecular and anatomic imaging could lead to more personalized surgical approaches based on both technical feasibility and biological risk.
Advertisement
Related to this article

Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
5


